Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolut...

Full description

Bibliographic Details
Main Author: Theys, Kristof (author)
Other Authors: Abecasis, Ana (author), Libina, Pieter (author), Gomes, Perpétua (author), Cabanas, Joaquim (author), Camacho, Ricardo J. (author), Van Laethem, Kristel (author)
Format: article
Language:eng
Published: 2017
Subjects:
HIV-1
dolutegravir
integrase
interpretation
resistance
treatment
Online Access:http://hdl.handle.net/10400.26/18392
Country:Portugal
Oai:oai:comum.rcaap.pt:10400.26/18392

Internet

http://hdl.handle.net/10400.26/18392

Similar Items